News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA and European Medicines Evaluation Agency Grant Orphan Drug Designation for ANTISENSE PHARMA GmbH's Investigational Drug Trabedersen in Pancreatic Carcinoma


9/14/2009 10:20:30 AM

REGENSBURG, Germany--(BUSINESS WIRE)--The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma. Trabedersen has already been granted orphan drug designation by both authorities in the treatment of high-grade gliomas in 2002. This underlines the high potential of trabedersen to treat various aggressive tumors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES